stockrowPulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
Follow PLSE
Alert me
Pulse Biosciences, Inc (PLSE) Return on equity
Pulse Biosciences, Inc's return on equity over the twelve months to 30 September 2026 was −60.7%, up 13.8 percentage points from fiscal 2025 (−74.5%). Over the past ten years it has ranged from −349.9% (fiscal 2022) to −14.4% (fiscal 2015); the current reading is higher than 55% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −74.5% | (7.14) |
| FY2024 | −67.3% | 133.16 |
| FY2023 | −200.5% | 149.42 |
| FY2022 | −349.9% | (132.56) |
| FY2021 | −217.3% | (31.43) |
| FY2020 | −185.9% | (89.12) |
| FY2019 | −96.8% | (29.93) |
| FY2018 | −66.9% | 4.87 |
| FY2017 | −71.7% | (22.86) |
| FY2016 | −48.9% | (34.43) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| NVST Envista Holdings Corporation compare | 20.5% |
| MMSI Merit Medical Systems, Inc. compare | 9.78% |
| STVN Stevanato Group S.p.A. compare | 9.22% |
| ATRC AtriCure, Inc. compare | 2.95% |
| ICUI ICU Medical, Inc. compare | 2.79% |
| WRBY Warby Parker Inc. compare | 1.93% |
| MMED MiniMed Group, Inc. compare | 0.00% |
| TFX Teleflex Incorporated compare | −28.9% |
| PLSE Pulse Biosciences, Inc | −60.7% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PLSE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement